David Kandzari, MD

All posts by David Kandzari, MD

RSS

July 25th, 2012

DES in Patients at Low Risk for TVR: Is the Benefit Worth the Cost? (Part I)

, , , and

In a recent article in Archives of Internal Medicine, researchers performed an analysis of current use of drug-eluting stents (DES) in patients at various levels of risk for target-vessel revascularization (TVR), and estimated the cost and clinical outcomes of using BMS rather than DES in patients at low risk (see News). To gauge reaction to […]